Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001

<p>Abstract</p> <p>Background</p> <p>In Australia in June 2001, a unique pneumococcal vaccine schedule commenced for Indigenous infants; seven-valent pneumococcal conjugate vaccine (7PCV) given at 2, 4, and 6 months of age and 23-valent pneumococcal polysaccharide vacci...

Full description

Bibliographic Details
Main Authors: Stubbs Liz, Wilson Cate A, McCallum Gabrielle B, Morris Peter S, Leach Amanda J, Beissbarth Jemima, Jacups Susan, Hare Kim, Smith-Vaughan Heidi C
Format: Article
Language:English
Published: BMC 2009-08-01
Series:BMC Infectious Diseases
Online Access:http://www.biomedcentral.com/1471-2334/9/121
id doaj-05f8d910380c4a3186a51191816a6961
record_format Article
spelling doaj-05f8d910380c4a3186a51191816a69612020-11-25T03:11:12ZengBMCBMC Infectious Diseases1471-23342009-08-019112110.1186/1471-2334-9-121Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001Stubbs LizWilson Cate AMcCallum Gabrielle BMorris Peter SLeach Amanda JBeissbarth JemimaJacups SusanHare KimSmith-Vaughan Heidi C<p>Abstract</p> <p>Background</p> <p>In Australia in June 2001, a unique pneumococcal vaccine schedule commenced for Indigenous infants; seven-valent pneumococcal conjugate vaccine (7PCV) given at 2, 4, and 6 months of age and 23-valent pneumococcal polysaccharide vaccine (23PPV) at 18 months of age. This study presents carriage serotypes following this schedule.</p> <p>Methods</p> <p>We conducted cross sectional surveys of pneumococcal carriage in Aboriginal children 0 to 6 years of age living in remote Aboriginal communities (RACs) in 2003 and 2005. Nasal secretions were collected and processed according to published methods.</p> <p>Results</p> <p>902 children (mean age 25 months) living in 29 communities in 2003 and 818 children (mean age 35 months) in 17 communities in 2005 were enrolled. 87% children in 2003 and 96% in 2005 had received two or more doses of 7PCV. From 2003 to 2005, pneumococcal carriage was reduced from 82% to 76% and reductions were apparent in all age groups; 7PCV-type carriage was reduced from 11% to 8%, and 23PPV-non-7PCV-type carriage from 31% to 25% respectively. Thus non-23PPV-type carriage increased from 57% to 67%. All these changes were statistically significant, as were changes for some specific serotypes. Shifts could not be attributed to vaccination alone. The top 10 of 40 serotypes identified were (in descending order) 16F, 19A, 11A, 6C, 23B, 19F, 6A, 35B, 6B, 10A and 35B. Carriage of penicillin non-susceptible (MIC > = 0.12 μg/mL) strains (15% overall) was detected in serotypes (descending order) 19A, 19F, 6B, 16F, 11A, 9V, 23B, and in 4 additional serotypes. Carriage of azithromycin resistant (MIC > = 2 μg/mL) strains (5% overall), was detected in serotypes (descending order) 23B, 17F, 9N, 6B, 6A, 11A, 23F, and in 10 additional serotypes including 6C.</p> <p>Conclusion</p> <p>Pneumococcal carriage remains high (~80%) in this vaccinated population. Uptake of both pneumococcal vaccines increased, and carriage was reduced between 2003 and 2005. Predominant serotypes in combined years were 16F, 19A, 11A, 6C and 23B. Antimicrobial non-susceptibility was detected in these and 17 additional serotypes. Shifts in serotype-specific carriage suggest a need more research to clarify the association between pneumococcal vaccination and carriage at the serotype level.</p> http://www.biomedcentral.com/1471-2334/9/121
collection DOAJ
language English
format Article
sources DOAJ
author Stubbs Liz
Wilson Cate A
McCallum Gabrielle B
Morris Peter S
Leach Amanda J
Beissbarth Jemima
Jacups Susan
Hare Kim
Smith-Vaughan Heidi C
spellingShingle Stubbs Liz
Wilson Cate A
McCallum Gabrielle B
Morris Peter S
Leach Amanda J
Beissbarth Jemima
Jacups Susan
Hare Kim
Smith-Vaughan Heidi C
Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
BMC Infectious Diseases
author_facet Stubbs Liz
Wilson Cate A
McCallum Gabrielle B
Morris Peter S
Leach Amanda J
Beissbarth Jemima
Jacups Susan
Hare Kim
Smith-Vaughan Heidi C
author_sort Stubbs Liz
title Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
title_short Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
title_full Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
title_fullStr Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
title_full_unstemmed Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
title_sort emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
publisher BMC
series BMC Infectious Diseases
issn 1471-2334
publishDate 2009-08-01
description <p>Abstract</p> <p>Background</p> <p>In Australia in June 2001, a unique pneumococcal vaccine schedule commenced for Indigenous infants; seven-valent pneumococcal conjugate vaccine (7PCV) given at 2, 4, and 6 months of age and 23-valent pneumococcal polysaccharide vaccine (23PPV) at 18 months of age. This study presents carriage serotypes following this schedule.</p> <p>Methods</p> <p>We conducted cross sectional surveys of pneumococcal carriage in Aboriginal children 0 to 6 years of age living in remote Aboriginal communities (RACs) in 2003 and 2005. Nasal secretions were collected and processed according to published methods.</p> <p>Results</p> <p>902 children (mean age 25 months) living in 29 communities in 2003 and 818 children (mean age 35 months) in 17 communities in 2005 were enrolled. 87% children in 2003 and 96% in 2005 had received two or more doses of 7PCV. From 2003 to 2005, pneumococcal carriage was reduced from 82% to 76% and reductions were apparent in all age groups; 7PCV-type carriage was reduced from 11% to 8%, and 23PPV-non-7PCV-type carriage from 31% to 25% respectively. Thus non-23PPV-type carriage increased from 57% to 67%. All these changes were statistically significant, as were changes for some specific serotypes. Shifts could not be attributed to vaccination alone. The top 10 of 40 serotypes identified were (in descending order) 16F, 19A, 11A, 6C, 23B, 19F, 6A, 35B, 6B, 10A and 35B. Carriage of penicillin non-susceptible (MIC > = 0.12 μg/mL) strains (15% overall) was detected in serotypes (descending order) 19A, 19F, 6B, 16F, 11A, 9V, 23B, and in 4 additional serotypes. Carriage of azithromycin resistant (MIC > = 2 μg/mL) strains (5% overall), was detected in serotypes (descending order) 23B, 17F, 9N, 6B, 6A, 11A, 23F, and in 10 additional serotypes including 6C.</p> <p>Conclusion</p> <p>Pneumococcal carriage remains high (~80%) in this vaccinated population. Uptake of both pneumococcal vaccines increased, and carriage was reduced between 2003 and 2005. Predominant serotypes in combined years were 16F, 19A, 11A, 6C and 23B. Antimicrobial non-susceptibility was detected in these and 17 additional serotypes. Shifts in serotype-specific carriage suggest a need more research to clarify the association between pneumococcal vaccination and carriage at the serotype level.</p>
url http://www.biomedcentral.com/1471-2334/9/121
work_keys_str_mv AT stubbsliz emergingpneumococcalcarriageserotypesinahighriskpopulationreceivinguniversal7valentpneumococcalconjugatevaccineand23valentpolysaccharidevaccinesince2001
AT wilsoncatea emergingpneumococcalcarriageserotypesinahighriskpopulationreceivinguniversal7valentpneumococcalconjugatevaccineand23valentpolysaccharidevaccinesince2001
AT mccallumgabrielleb emergingpneumococcalcarriageserotypesinahighriskpopulationreceivinguniversal7valentpneumococcalconjugatevaccineand23valentpolysaccharidevaccinesince2001
AT morrispeters emergingpneumococcalcarriageserotypesinahighriskpopulationreceivinguniversal7valentpneumococcalconjugatevaccineand23valentpolysaccharidevaccinesince2001
AT leachamandaj emergingpneumococcalcarriageserotypesinahighriskpopulationreceivinguniversal7valentpneumococcalconjugatevaccineand23valentpolysaccharidevaccinesince2001
AT beissbarthjemima emergingpneumococcalcarriageserotypesinahighriskpopulationreceivinguniversal7valentpneumococcalconjugatevaccineand23valentpolysaccharidevaccinesince2001
AT jacupssusan emergingpneumococcalcarriageserotypesinahighriskpopulationreceivinguniversal7valentpneumococcalconjugatevaccineand23valentpolysaccharidevaccinesince2001
AT harekim emergingpneumococcalcarriageserotypesinahighriskpopulationreceivinguniversal7valentpneumococcalconjugatevaccineand23valentpolysaccharidevaccinesince2001
AT smithvaughanheidic emergingpneumococcalcarriageserotypesinahighriskpopulationreceivinguniversal7valentpneumococcalconjugatevaccineand23valentpolysaccharidevaccinesince2001
_version_ 1724655544076075008